Cobra wins Replikun Biotech contract for gene therapy support
Cobra Biomanufacturing located at Keele, UK, has signed a contract with the Australia's Replikun Biotech to support the development of an innovative gene therapy method. Cobra specialises in producing DNA, virus, cellular therapeutics and recombinant protein products, and will construct and establish a packaging cell line producing KUN-GMCSF, a potent and novel gene therapy system for the treatment of cancer.
Cobra Biomanufacturing located at Keele, UK, has signed a contract with the Australia's Replikun Biotech to support the development of an innovative gene therapy method. Cobra specialises in producing DNA, virus, cellular therapeutics and recombinant protein products, and will construct and establish a packaging cell line producing KUN-GMCSF, a potent and novel gene therapy system for the treatment of cancer.
KUN-GMCSF enables the expression of a protein in human cells that stimulates the immune system to overcome a tumour's ability to evade the immune system. It uses a novel gene delivery approach based on a proprietary vector system (Kunrep Vector Systems), derived from the Kunjin virus and developed by Replikun Biotech.
Dr Shane Storey, ceo of Replikun, said: 'We are very impressed with Cobra's expertise in the manufacture of novel viruses and vector systems and are confident that it will deliver the cell lines in time and with the highest quality as required for our KUN-GMCSF programme.'
Cobra has facilities in Keele and Oxford, UK.